Research Topics
| Kimberly A StiglerSummaryAffiliation: Indiana University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Paliperidone for irritability in adolescents and young adults with autistic disorderKimberly A Stigler
Section of Child and Adolescent Psychiatry, Department of Psychiatry, Indiana University School of Medicine, Christian Sarkine Autism Treatment Center, James Whitcomb Riley Hospital for Children, 705 Riley Hospital Drive, Indianapolis, IN 46202 5200, USA
Psychopharmacology (Berl) 223:237-45. 2012..Despite advances in the treatment of this symptom domain in autism, there remains an ongoing need for more effective and better tolerated pharmacotherapies...
Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label studyKimberly A Stigler
Department of Psychiatry, Section of Child and Adolescent Psychiatry, Indiana University School of Medicine and Christian Sarkine Autism Treatment Center, James Whitcomb Riley Hospital for Children, Indianapolis, Indiana 46202 5200, USA
J Child Adolesc Psychopharmacol 19:265-74. 2009..The aim of this study was to determine the effectiveness and tolerability of aripiprazole for irritability in pervasive developmental disorder not otherwise specified (PDD-NOS) and Asperger's disorder...
Ramelteon for insomnia in two youths with autistic disorderKimberly A Stigler
Department of Psychiatry, Indiana University School of Medicine and the Christian Sarkine Autism Treatment Center at the James Whitcomb Riley Hospital for Children, Indianapolis, Indiana 46202 5200, USA
J Child Adolesc Psychopharmacol 16:631-6. 2006..The aim of this study was to report preliminary data on the effectiveness and tolerability of ramelteon for the treatment of insomnia in youth with autistic disorder (autism)...- Structural and functional magnetic resonance imaging of autism spectrum disordersKimberly A Stigler
Christian Sarkine Autism Treatment Center, James Whitcomb Riley Hospital for Children, Indianapolis, IN 46202 5200, USA
Brain Res 1380:146-61. 2011..Overall, structural and functional MRI research has generated important insights into the neurobiology of ASDs. Additional research is needed to further delineate the underlying brain basis of this constellation of disorders... - A prospective open-label study of aripiprazole in fragile X syndromeCraig A Erickson
Department of Psychiatry, Indiana University School of Medicine, 702 Barnhill Drive, Indianapolis, IN 46202, USA
Psychopharmacology (Berl) 216:85-90. 2011..Despite frequent clinical use of atypical antipsychotic drugs to target this behavioral cluster, no systematic trials to date have assessed the efficacy and safety of these drugs in persons with FXS... - Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disordersChristopher J McDougle
Department of Psychiatry, Indiana University School of Medicine, Christian Sarkine Autism Treatment Center, James Whitcomb Riley Hospital for Children, Indianapolis, IN 46202 4800, USA
J Clin Psychiatry 69:15-20. 2008..Additional placebo-controlled trials and studies of longer-term safety and tolerability are needed... - The effects of aripiprazole on electrocardiography in children with pervasive developmental disordersJason G Ho
Section of Pediatric Cardiology, Department of Pediatrics, James Whitcomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana 46202 5200, USA
J Child Adolesc Psychopharmacol 22:277-83. 2012..Adult studies have evaluated aripiprazole's effects on electrocardiograms, but no pediatric studies have been published to date... - Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disordersDavid J Posey
Department of Psychiatry and Christian Sarkine Autism Treatment Center at the Indiana University School of Medicine, Indianapolis, Indiana, USA
J Child Adolesc Psychopharmacol 16:599-610. 2006..The aim of this study was to conduct an initial evaluation of the efficacy of atomoxetine for attention-deficit/hyperactivity disorder (ADHD) symptoms in children with pervasive developmental disorders (PDDs)... - A retrospective analysis of quetiapine in the treatment of pervasive developmental disordersAdam H Corson
Department of Psychiatry, Indiana University School of Medicine and Christian Sarkine Autism Treatment Center, James Whitcomb Riley Hospital for Children, Indianapolis, Ind. 46202-4800, USA
J Clin Psychiatry 65:1531-6. 2004..CONCLUSION: Quetiapine was modestly effective for maladaptive behavior in patients with a PDD. Controlled studies are needed to further assess these preliminary findings... - Pharmacotherapy of irritability in pervasive developmental disordersKimberly A Stigler
Department of Psychiatry, Indiana University School of Medicine, Riley Hospital for Children, Room 4300, 702 Barnhill Drive, Indianapolis, IN 46202 5200, USA
Child Adolesc Psychiatr Clin N Am 17:739-52, vii-viii. 2008..Additional large-scale, placebo-controlled studies of other medications are needed to determine their efficacy for the treatment of irritability in this diagnostic group... - An open-label naturalistic pilot study of acamprosate in youth with autistic disorderCraig A Erickson
Department of Psychiatry, Christian Sarkine Autism Treatment Center, Indiana University School of Medicine, James Whitcomb Riley Hospital for Children, Indianapolis, Indiana 46202, USA
J Child Adolesc Psychopharmacol 21:565-9. 2011..Acamprosate was well tolerated with only mild gastrointestinal adverse effects noted in three (50%) subjects... - Antipsychotics in the treatment of autismDavid J Posey
Christian Sarkine Autism Treatment Center, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
J Clin Invest 118:6-14. 2008..Significant adverse effects, including weight gain and the possibility of tardive dyskinesia, are reviewed. Future research directions are discussed... - Risperidone in pervasive developmental disordersCraig A Erickson
Riley Hospital, Child and Adolescent Psychiatry Clinic, 702 Barnhill Drive, ROC 4300, Indianapolis, IN 46202, USA
Expert Rev Neurother 5:713-9. 2005..Finally, a discussion of the future direction of risperidone use in this population and key issues will be presented... - A retrospective study of memantine in children and adolescents with pervasive developmental disordersCraig A Erickson
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA
Psychopharmacology (Berl) 191:141-7. 2007..There are no drugs that have been shown to effectively treat the core social impairment of autism... - Aripiprazole in autism spectrum disorders and fragile X syndromeCraig A Erickson
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
Neurotherapeutics 7:258-63. 2010..However, research to date in this disorder has not focused on this target symptom cluster. An initial pilot study has begun to assess the impact of aripiprazole on irritability in youth with fragile X syndrome... - Open-label riluzole in fragile X syndromeCraig A Erickson
Department of Psychiatry, Indiana University School of Medicine, James Whitcomb Riley Hospital for Children, Indianapolis, IN 46202, USA
Brain Res 1380:264-70. 2011..Correction of delayed ERK activation is a potential biomarker of treatment response in FXS. We conducted a six-week open-label prospective pilot study of riluzole (100 mg/day) in six adults with FXS... - Pharmacologic treatment of autism and related disordersCraig A Erickson
Department of Psychiatry, Indiana University School of Medicine, and the Christian Sarkine Autism Treatment Center, James Whitcomb Riley Hospital for Children, Indianapolis 46202-4800, USA
Pediatr Ann 36:575-85. 2007 - Aripiprazole for maladaptive behavior in pervasive developmental disordersKimberly A Stigler
Department of Psychiatry, Indiana University School of Medicine and the James Whitcomb Riley Hospital for Children, Indianapolis, IN 46202, USA
J Child Adolesc Psychopharmacol 14:455-63. 2004..No significant adverse effects emerged during these short-term trials. Additional research is needed to support these preliminary findings... - The use of selective serotonin reuptake inhibitors in autism and related disordersDavid J Posey
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
J Child Adolesc Psychopharmacol 16:181-6. 2006..Larger, placebo-controlled studies of SSRIs are needed to guide clinical treatment... - A naturalistic retrospective analysis of psychostimulants in pervasive developmental disordersKimberly A Stigler
Department of Psychiatry, Indiana University School of Medicine, James Whitcomb Riley Hospital for Children, Indianapolis, Indiana, USA
J Child Adolesc Psychopharmacol 14:49-56. 2004..Response may differ with PDD subtype. Controlled studies are needed to further evaluate these preliminary findings in a systematic manner... - Gastrointestinal factors in autistic disorder: a critical reviewCraig A Erickson
Department of Psychiatry, Indiana University School of Medicine, Indianapolis 46202-4800, USA
J Autism Dev Disord 35:713-27. 2005..While much literature is available on this topic, a dearth of rigorous study was found to validate GI factors specific to children with autism... - Neurochemistry in the pathophysiology of autismChristopher J McDougle
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202 4800, USA
J Clin Psychiatry 66:9-18. 2005..As these efforts move forward, it will be important to begin to integrate genetic studies with those involving neuroimaging and postmortem research in each of these 3 areas, as well as with pharmacologic treatment approaches... - Emerging drugs for the treatment of symptoms associated with autism spectrum disordersLogan K Wink
Indiana University School of Medicine, Department of Psychiatry, Indianapolis, IN 46202, USA
Expert Opin Emerg Drugs 15:481-94. 2010..The use of pharmacologic agents in the treatment of these disorders can reduce the impact of interfering symptoms, providing relief for affected individuals and their families... - Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and managementKimberly A Stigler
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana 46202-4800, USA
Paediatr Drugs 6:33-44. 2004.... - Treatment of aggression in children and adolescents with autism and conduct disorderChristopher J McDougle
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202, USA
J Clin Psychiatry 64:16-25. 2003.... - Developmental disabilities modification of the Children's Global Assessment ScaleAnn Wagner
National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
Biol Psychiatry 61:504-11. 2007..To measure global functioning in treatment studies, the Children's Global Assessment Scale was modified and psychometric properties of the revised version (DD-CGAS) were assessed in children with PDD...